UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioblastoma (grade IV)
Glioma
Summary
This is a Phase 1 study to evaluate the safety, pharmacokinetic, pharmacodynamic, and preliminary antitumor activity of orally administered DSP-0390 in patients with recurrent high-grade glioma. Patients in this study will receive DSP-0390 orally once daily.
Conditions
Glioma
Glioblastoma (grade IV)
The purpose of this Phase I/IIa clinical trial is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of FORE8394 in participants with advanced solid tumors, advanced, unresectable solid tumors with activating BRAF mutations, or primary central nervous system (CNS) tumors harboring BRAF mutations.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioblastoma (grade IV)
Glioma
This phase II study will evaluate the safety and efficacy of berubicin for people with recurrent glioblastoma multiforme. Berubicin is a novel anthracycline-based topoisomerase II inhibitor that crosses the blood-brain barrier and overcomes drug resistance.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Conditions
Glioma
Meningioma
Astrocytoma
Oligodendroglioma
The goal of this prospective cross-sectional study is to establish the content validity of the available patient-reported outcome (PRO) measures used in primary and secondary brain tumor patients.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase II clinical trial will evaluate the efficacy of dabrafenib and trametinib after radiation therapy in children and young adults with BRAF V600 mutant high-grade glioma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
This is a pilot study to develop a liquid biomarker of hypermutation in glioma patients previously treated with the chemotherapy temozolomide.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.